Table 2.

Infant characteristics and outcomes

	Intervention (n=177)	Control (n=203)	Combined (n=380)
Girls	84 (47%)	104 (51%)	188 (49%)
Gestational age at delivery (weeks)	38 (36–39)	38 (38–40)	38 (36–39)
Birthweight (kg)	3·0 (2·6–3·2)	2·8 (2·5–3·1)	2·9 (2·5–3·1)
Missing	14 (8%)	19 (9%)	33 (9%)
Birth length (m)	0·49 (0·47–0·51)	0·49 (0·48–0·50)	0·49 (0·48–0·50)
Missing	14 (8%)	28 (14%)	42 (11%)
Infant antiretroviral regimen at birth
Daily nevirapine	159 (90%)	151 (74%)	310 (82%)
None	18 (10%)	52 (26%)	70 (18%)
Breastfeeding status
Missing	35 (20%)	72 (35%)	107 (28%)
Ever breastfed*	140 (99%)	131 (100%)	271 (99%)
Never breastfed*	2 (1%)	0	2 (1%)
Infant death	28 (16%)	42 (21%)	70 (18%)
Cause of infant death†
Missing	0	1 (2%)	1 (1%)
Stillbirth or miscarriage	11 (39%)	18 (44%)	29 (41%)
Birth complication	1 (4%)	4 (10%)	5 (7%)
HIV-associated illness (eg, antiretroviral drug side-effect or opportunistic infection)	1 (4%)	1 (2%)	2 (3%)
Non-HIV-associated illness	0	1 (2%)	1 (1%)
Accidental	1 (4%)	1 (2%)	2 (3%)
Unknown	13 (46%)	15 (37%)	28 (41%)
Other	1 (4%)	1 (2%)	2 (3%)
Cumulative infant HIV incidence (%)‡
6 weeks	1·8% (0·6–5·4)	6·0% (2·5–14·0)	3·2% (1·6–6·2)
12 weeks	2·4% (0·9–6·3)	7·3% (3·3–15·6)	4·0% (2·2–7·3)
Infant mortality (%)‡
6 weeks	13·7% (8·5–18·7)	19·6% (12·1–26·4)	15·9% (11·7–19·9)
12 weeks	15·0% (9·5–20·1)	25·1% (16·2–33·1)	18·5% (13·9–22·8)

Data are n (%), median (IQR), or % (95% CI).

^*Denominator for percentages is number of infants for whom data were available.

^†Denominator for percentages is number of deceased infants.

^‡All infants are included in this analysis. Infants are censored at loss to follow-up (off-study date).